Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan as…
Measurement & Standards
Explore the main themes, entities and connections around Etretinate. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
birth market half-life years defects tigason therapy fda 1996 united states due risk japan acitretin effects withdrawn elimination trade name
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Etretinate | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Etretinate | AHFS/Drugs.com | Drugs.com archive | 1.00 | infobox |
| Etretinate | ATC code | D05BB01 (WHO) | 1.00 | infobox |
| Etretinate | CAS Number | 54350-48-0 N | 1.00 | infobox |
| Etretinate | ChEBI | CHEBI:4913 Y | 1.00 | infobox |
| Etretinate | ChEMBL | ChEMBL464 Y | 1.00 | infobox |
| Etretinate | ChemSpider | 4445538 Y | 1.00 | infobox |
| Etretinate | CompTox Dashboard (EPA) | DTXSID0023036 | 1.00 | infobox |
| Etretinate | DrugBank | DB00926 Y | 1.00 | infobox |
| Etretinate | ECHA InfoCard | 100.053.727 | 1.00 | infobox |
| Etretinate | Elimination half-life | 120 days | 1.00 | infobox |
| Etretinate | Formula | C23H30O3 | 1.00 | infobox |
| Etretinate | IUPHAR/BPS | 7599 | 1.00 | infobox |
| Etretinate | KEGG | D00316 Y | 1.00 | infobox |
| Etretinate | Legal status | BR: Class F4 (Other prohibited substances) | 1.00 | infobox |
| Etretinate | Legal status | US: Withdrawn | 1.00 | infobox |
| Etretinate | MedlinePlus | a601010 | 1.00 | infobox |
| Etretinate | Metabolites | Free acid, Z-form, chain shortening | 1.00 | infobox |
| Etretinate | Molar mass | 354.490 g·mol−1 | 1.00 | infobox |
| Etretinate | Protein binding | >99% | 1.00 | infobox |
| Etretinate | PubChem CID | 5282375 | 1.00 | infobox |
| Etretinate | Routes of administration | Oral | 1.00 | infobox |
| Etretinate | Trade names | Tigason, formerly Tegison | 1.00 | infobox |
| Etretinate | UNII | 65M2UDR9AG | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.